Precigen (PGEN) Non-Current Assets (2012 - 2026)
Precigen (PGEN) posted quarterly Non-Current Assets of $37.0 million for Q1 2026, down 16.36% year-over-year from $44.2 million in Q1 2025, and down 8.23% quarter-over-quarter from $40.3 million in Q4 2025.
Precigen (PGEN) Non-Current Assets (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Non-Current Assets for 15 consecutive years, with $37.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 16.36% year-over-year to $37.0 million; the TTM figure through Mar 2026 stood at $158.0 million (down 14.78% YoY), while the FY2025 annual figure was $40.3 million, down 6.03% from the prior year.
- Non-Current Assets slipped to $37.0 million in Q1 2026 per PGEN's latest filing, from $40.3 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $180.6 million in Q1 2022 and bottomed at $37.0 million in Q1 2026.
- Historically, Non-Current Assets has averaged $79.2 million across 5 years, with a median of $82.3 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets plunged 56.91% — and 2023, when it rose 1.31%.
- Precigen's Non-Current Assets stood at $97.8 million in 2022, then decreased by 15.88% to $82.3 million in 2023, then tumbled by 47.92% to $42.9 million in 2024, then decreased by 6.03% to $40.3 million in 2025, then declined by 8.23% to $37.0 million in 2026.
- Business Quant data shows PGEN's Non-Current Assets at $37.0 million in Q1 2026, $40.3 million in Q4 2025, and $41.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 35.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.91 Mn |
| Mar 31, 2026 | 36.96 Mn |
| Dec 31, 2025 | 40.27 Mn |
| Sep 30, 2025 | 41.67 Mn |
| Jun 30, 2025 | 39.14 Mn |
| Mar 31, 2025 | 44.19 Mn |
| Dec 31, 2024 | 42.85 Mn |
| Sep 30, 2024 | 48.96 Mn |
| Jun 30, 2024 | 49.45 Mn |
| Mar 31, 2024 | 85.30 Mn |
| Dec 31, 2023 | 82.29 Mn |
| Sep 30, 2023 | 97.70 Mn |
| Jun 30, 2023 | 101.90 Mn |
| Mar 31, 2023 | 103.80 Mn |
| Dec 31, 2022 | 97.82 Mn |
| Sep 30, 2022 | 96.44 Mn |
| Jun 30, 2022 | 156.61 Mn |
| Mar 31, 2022 | 180.63 Mn |
| Dec 31, 2021 | 203.23 Mn |
| Sep 30, 2021 | 223.81 Mn |